Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356038 | 0.85 | HPGD (0.44) | NAAAEPHX1EPHX2ALDH1A1HTT | |
| SCHEMBL4355852 | 0.85 | EPHX2 (0.48) | NAAAEPHX1EPHX2ALDH1A1HTT | |
| SCHEMBL4349401 | 0.81 | MGLL (0.38) | NAAAEPHX1EPHX2TRPV1SMN1; SMN2 | |
| SCHEMBL4355899 | 0.80 | RAB9A (0.53) | EPHX1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4354053 | 0.79 | TRPV1 (0.44) | NAAAEPHX1EPHX2TRPV1SMN1; SMN2 | |
| SCHEMBL4349848 | 0.75 | KMT2A (0.44) | ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL4133486 | 0.75 | NAAA (0.49) | NAAAEPHX1EPHX2ALDH1A1HTT | |
| SCHEMBL4350102 | 0.74 | TRPV1 (0.49) | NAAAEPHX2TRPV1 | |
| SCHEMBL4346809 | 0.74 | TRPV1 (0.46) | NAAAEPHX1EPHX2ALDH1A1TRPV1 | |
| SCHEMBL4352149 | 0.74 | ERN1 (0.38) | ALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | NAAA 2425/4885EPHX1 1676/4885EPHX2 769/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | NAAA 2193/4885EPHX1 1334/4885EPHX2 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.